Indian generic pharmaceutical trading
WHO-GMP and PIC/S certified supply network
Active in Southeast Asia and CIS — expanding to Middle East
While others arrive with a catalogue, Aravis arrives having mapped your market, identified portfolio gaps, and prepared documentation-ready proposals — before the first conversation.
The gap between what a market needs and what it receives is a sourcing problem. Aravis solves it before it becomes one.
Therapy areas
Every molecule we propose is backed by technical documentation compiled to the regulatory standard of your market — the filing work is done before the commercial conversation begins.
View full portfolio →Molecules across Anti-Infectives, Cardiovascular & Metabolic, and CNS
Myanmar, Georgia, Turkmenistan, Tajikistan
Registered across active markets — 400+ in documentation review
One Star Export House, Ministry of Commerce, India
How we work
Most trading companies treat the first distributor conversation as the starting point. Aravis treats it as the midpoint. The market analysis, the gap identification, the documentation review — that work is complete before we pick up the phone. This is not a sales advantage. It is an operational discipline. And it is the reason distributors who engage with us move to commercial terms faster than with any other supplier.
Manufacturing
Immediate and extended-release formulations across cardiovascular, diabetes, CNS, and anti-infectives. Full ER / MR capability including sustained-release combinations — Pregabalin SR + Methylcobalamin, Metoprolol Succinate ER, Divalproex Sodium ER. Dispersible tablets and dry syrups included.
Small-volume parenterals across the full anti-infective spectrum — cephalosporins, carbapenems, reserve-class antibiotics, antifungals, and corticosteroids. Lyophilised and liquid formats. Sterile manufacturing to BP, USP, and IP standards throughout.
Sterile large-volume parenterals. Sodium chloride, dextrose, metronidazole, levofloxacin, paracetamol, and mannitol infusions. Glass and plastic containers. Terminally sterilised to WHO GMP standard.
Most Indian generic trading companies cannot source IV infusions competitively. This capability opens institutional and hospital accounts that other suppliers cannot reach.
Pressurised metered-dose inhalers, aqueous nasal sprays, and sterile ophthalmic drops. MDI manufacturing requires specialist pressurised filling capability — separate from standard sterile injectable lines. Ophthalmic range includes preservative-free formulations and combination antibiotic-steroid drops.
47 MDI and nasal spray molecules. 175 ophthalmic molecules across glaucoma, anti-infective, anti-inflammatory, and lubricant categories.
Markets
We operate in markets where we have named distribution partners, active registrations, and filed dossiers. We do not list markets we are exploring as markets we are in.
We are selective about where we expand. New market entries follow the same preparedness methodology as our current markets — analysis first, registrations second, distribution partnerships third. If you represent a distributor or importer in a market we have not yet entered, we are open to the conversation.
Tell us your target market and what you import. We will assess whether our portfolio is a genuine fit — and come back with a molecule gap analysis if it is.
We respond to enquiries from registered importers, licensed distributors, and pharmacy chains with demonstrated market presence. Volume and regulatory context help us respond meaningfully.